AllDocs -> cancers

Cahaba Government Benefit Administrators A CMS Contracted Fiscal Intermediary 400 E. Court Avenue Des Moines, IA 50309-2017 Liver Disease Revision # RETIRED: 07/31/2003 Contractor's Policy Number OA 98006 THIS POLICY HAS BEEN RETIRED AND IS NO LONGER IN EFFECT. Contractor Name Cahaba Government Benefit Administrators Contractor Number 000011 Contractor Type Fiscal Intermediary LMRP Title HOSPICE - DETERMINING TERMINAL STATUS IN NON- CANCER DIAGNOSES - LIVER DISEASE THIS POLICY HAS BEEN RETIRED AND IS NO LONGER IN EFFECT. AMA CPT Copyright Statement CPT codes, descriptions, and other data only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply CMS National Coverage Policy • Social Security Act, Secs. 1102, 1812(a)(4) ...

P.1 Novel Treatment for Primary Liver Cancer Joint Universities and Biotechnological Industry in Drug Development Dr Tung-ping Poon, Ronnie, Assistant Dean (Research), Faculty of Medicine, The University of Hong Kong Dr Ning-man Cheng, Paul, Adjunct Associate Professor, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University Dr Yun-chung Leung, Thomas, Lecturer, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University Dr Wai-hung Lo, Thomas, Lecturer, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University Hepatocellular carcinoma (HCC) is one of the five most common human cancers worldwide. It is the second leading cause of cancer death in Hong Kong. About 1,500 new patients are identified every year. According ...

Concepts in Local Therapy For Liver Cancer D. C. Mulligan, M.D., FACS, Chair, Division of Transplantation Surgery, Mayo Clinic Arizona, 13400 E. Shea Boulevard, Scottsdale, AZ 85259 Throughout the world, hepatic malignancies are rapidly becoming more abundant. Hepatocellular carcinoma(HCC) is responsible for more than 1 million deaths yearly and will undoubtedly continue to rise due to the increasing prevalence of hepatitis C, which in the U.S. is approximately 4 million. Metastatic disease to the liver represents an even larger population, with over 150,000 new cases of colorectal cancer occurring in the U.S. per year and 20% of which will develop liver metastases early in the disease. Despite the bleak picture painted by these figures, a significant survival advantage may be offered to patients with primary and secondary hepatic malignancies, particularly when the disease is localized to the ...

Liver Cancer No. of cases registered in 2001 Rank in 2001 Relative frequency Male : Female ratio Median age (years) Crude rate World age-standardized rate Cumulative life-time risk (0-74 yrs) Mortality/Incidence ratio Time trends (Crude rate in bracket) -1991 1,131 (38.5) 314 (11.2) 861 (29.3) 258 (9.2) -1992 1,210 (41.1) 362 (12.7) 888 (30.1) 269 (9.4) -1993 1,272 (42.7) 365 (12.5) 914 (30.6) 254 (8.7) -1994 1,325 (43.6) 382 (12.8) 897 (29.5) 264 (8.8) -1995 1,184 (38.4) 405 (13.2) 916 (29.7) 300 (9.8) -1996 1,338 (41.6) 400 (12.4) 997 (31.0) 289 (9.0) -1997 1,289 (39.8) 412 (12.7) 979 (30.3) 285 (8.8) -1998 1,298 (39.9) 380 (11.5) 1,016 (31.3) ...

King’s College Hospital NHS Trust NHS Cancer of the liver : Hepatocellular carcinoma Information for patients and relatives Ki ng ’ s Page 2 What is the liver ? The liver is the largest solid organ within your body. It lies under the ribs, just below the lungs, under the diaphragm, on the right side of your body. It has two main lobes and is further divided into segments. Unlike other organs within the body, the liver has two main blood vessels that supply it with blood, oxygen and nutrients. The portal vein brings blood from the gut and accounts for 75% of the liver ’s blood supply. The hepatic artery brings blood from the heart and accounts for the remaining 25%. Liver tumours receive their blood supply from branches of the hepatic artery. The ...

Micronuclei and cell survival in human liver cancer cells irradiated by 25MeV/u 40 Ar 14+ * LI Wen-Jian 1 , GAO Qing-Xiang 2 , ZHOU Guang-Ming 1 and WEI Zeng-Quan 1 1 Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou 730000, Gansu Province, China 2 Department of Biology, Lanzhou University, Lanzhou 730000, Gansu Province, China LI Wen-Jian, male, born on 1959-02-22 in Hebei Province, Associate Professor and Deputy Director of the Second Division of Heavy Ion Application. Graduated and obtained a bachelor degree from Hebei University of Technology in 1982, and a master degree from Institute of Modern Physics, Chinese Academy of Sciences in 1992, specialized in the basic study of radiation biological effects and cancer therapy with heavy ions; having 33 papers published. ...

Growth-inhibiting effects of taxol on human liver cancer in vitro and in nude mice Jin Hui Yuan 1 , Ru Ping Zhang 1 , Ru Gang Zhang 1 , Li Xia Guo 1 , Xing Wang Wang 1 , Dan Luo 2 , Yong Xie 2 and Hong Xie 1 PO Box 2345, Beijing 100023, China World J Gastroentero, 2000; 6(2):210-215 Fax: +86-10-85381893 World Journal of Gastroenterology E-mail: wjg@wjgnet.com www.wjgnet.com Copyright 2000 by the WJG Press ISSN 1007-9327 Subject headings paclitaxel; liver neoplasms; apoptosis; mitoics; in vitro ; DNA; RNA; microscopy, wection; mice, nude Yuan JH, Zhang RP, Zhang RG, Guo LX, Wang XW, Luo D, Xie Y, Xie H. Growthinhibiting effects of taxol on human liver cancer in vitro and in nude mice. World J Gastroenterol, 2000;6(2):210-215 ...

Hepatitis Viruses and Liver Cancer Joint Symposium of Hepatitis Panel and Environmental Genomics and Carcinogenesis Panel December 8, 2004 14:30 - 14:35 Opening Remarks 14:35 - 15:05 John D. Groopman Hepatitis viruses and aflatoxin: A conspiracy in human liver cancer 15:05 - 15:35 Curtis C. Harris p53: at the crossroads of chemical-viral interactions in hepatocellular carcinogenesis 15:35 - 16:05 Kazuhiko Koike HCV-associated hepatocarcinogenesis: Lesson from animal model studies 16:05 - 16:20 Break 16:20 - 16:50 Kunitada Shimotohno Molecular interactions between HCV and host cells 16:50 - 17:20 Masao Omata Prevention and treatment of liver cancer 17:20 - 17:50 Timothy Block Glycobiology of viral hepatitis treatment and detection of liver cancer 17:50 - 17:55 Closing Remarks

EXPERIMENTAL and MOLECULAR MEDICINE, Vol. 33, No. 4, 179-190, December 2001 Chronic liver injury, TGF- ß , and cancer D. Montgomery Bissell 1,2 1 University of California, San Francisco 2 Corresponding author: Fax, +1-415-476-0659; E-mail, dmbiss@itsa.ucsf.edu Accepted 19 November 2001 Abbreviations: ECM, extracellular metrix; HSC, hepatic stellate cell; HCC, hepatocellular carcinoma Abstract Cells termed myofibroblasts are prominent in the injury response of all epithelial tissues. They exhibit proliferation, migration, production of collagen and other extracellular matrix (ECM) molecules, and con- traction, all for containing the injury and closing the wound. When the injury is limited in time, the final stage of the repair involves a dismantling of the cel- lular apparatus and restoration of normal tissue ...

New Treatment for Liver Cancer – Radiofrequency Ablation Primary liver cancer is the No.2 cancer killer in Hong Kong. About 1500 new patients are identified every year, and 1,381 people died of liver cancer in 2002. Currently, 4 methods are available for the treatment for liver cancer : surgical removal, liver transplantation, transarterial chemoembolization and radiofrequency ablation. Radiofrequency ablation (RFA) as a treatment for liver cancer has just been developed in the recent 4 to 5 years. A needle is inserted into the tumor through the skin, by laparoscope or by operation, and emits radiofrequency wave that causes vibration of the ions in the cancerous cells, which in turn produces frictional heat. Upon reaching 50 degree Celsius, protein in the cancerous cells solidifies and the cancerous cells die. RFA is suitable to treat patients with more than ...

J. RADIAT. RES., 42, 117–130 (2001) *Corresponding author: Phone: 81–822–61–1937, Fax: 81–822–62–9768, Email: sharp@rerf.or.jp Abbreviations: CC, cholangiocarcinoma; CI, confidence interval; HbsAg, hepatitis-B surface antigen; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; LET, linear-energy transfer; LSS, Life Span Study; OR, odds ratio; RBE, relative biologic effectiveness; RERF, Radiation Effects Research Foundation; Sv, Sievert Liver Cancer in Atomic-bomb Survivors: Histological Characteristics and Relationships to Radiation and Hepatitis B and C Viruses TOSHIYUKI FUKUHARA 1 , GERALD B. SHARP 2,3 * , TERUMI MIZUNO 4 , HIDEYO ITAKURA 5 , MASAMI YAMAMOTO 6 , MASAYOSHI TOKUNAGA 7 , SHOJI TOKUOKA 2 , JOHN B. COLOGNE 8 ...

Mefenamic acid-induced apoptosis in human liver cancer cell-lines through caspase-3 pathway Dong Ho Woo a , In-Seob Han b , Guhung Jung a, * a School of Biological Sciences, Seoul National University, Seoul 151-742, South Korea b Department of Biological Science, University of Ulsan, Ulsan 690-749, South Korea Received 8 October 2003; accepted 15 April 2004 Abstract Non-steroidal anti-inflammatory drugs (NSAIDs) have anti-proliferative effects and induce apoptosis in colon and other cancers. In the present study, we report that mefenamic acid (MEF), a member of NSAIDs, has an inhibitory effect on a proliferation of liver cancer cells. We used Chang and Huh-7 cells as human liver cancer cells. MEF-treated Huh-7 and Chang cells displayed apoptotic morphological changes and the portion of cells in sub G1 was ...

PO Box 2345, Beijing 100023, China World J Gastroenterol 2004;10(13):1867-1871 Fax: +86-10-85381893 World Journal of Gastroenterology E-mail: wjg@wjgnet.com www.wjgnet.com Copyright © 2004 by The WJG Press ISSN 1007-9327 • LIVER CANCER • Endostatin gene therapy for liver cancer by a recombinant adenovirus delivery Li Li, Jia-Ling Huang, Qi-Cai Liu, Pei-Hong Wu, Ran-Yi Liu, Yi-Xin Zeng, Wen-Lin Huang Li Li, Jia-Ling Huang, Ran-Yi Liu, Pei-Hong Wu, Yi-Xin Zeng, Wen-Lin Huang, Cancer Center, Sun Yat-sen University, 651 Dongfeng RoadEast, Guangzhou 510060,GuangdongProvince,China Qi-Cai Liu, Experimental Medical Research Center, Guangzhou Medical College, 195 Dongfeng Road West, Guangzhou 510182, Guangdong Province, China Supported by the National High Technology Research and Development Program of China (863 Program), No. 2003AA216061 ...

P.O.Box 2345, Beijing 100023,China World J Gastroenterol 2003;9(7):1618-1620 Fax: +86-10-85381893 World Journal of Gastroenterology E-mail: wjg@wjgnet.com www.wjgnet.com Copyright © 2003 by The WJG Press ISSN 1007-9327 • BRIEF REPORTS • Fatty metamorphosis of the liver in patients with breast cancer : Possible associated factors Cheng-Hsin Chu, Shee-Chan Lin, Shou-Chuan Shih, Chin-Roa Kao, Sun-Yen Chou Cheng-Hsin Chu, Shee-Chan Lin, Shou-Chuan Shih, Chin-Roa Kao, Sun-Yen Chou , Division of Gastroenterology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan, China Correspondence to: Dr. Cheng-Hsin Chu, Department of Hepatology and Gastroenterology, Mackay Memorial Hospital, Address: No. 92, Sec. 2, Chung-Shan N. Road, Taipei, Taiwan, China. suyu5288@ms14.hinet.net Telephone: +86-2-88661107 Fax: +86-2-25433642 ...

INTRODUCTION Ginseng has been used as a medicinal plant for more than 2000 yr in Asian countries. In fact, various pharmacological activities have been found in ginseng extract or its consti- tuents. Among them, anti-carcinogenic effect seems to be especially important, since development of effective method for cancer prevention is urgent problem not only in Asian countries but also in all over the world. Inhibitory effect of red ginseng extracts on pulmonary carcinogenesis has already been well documented (1). And tendency of suppression on liver carcinogensis has also reported (1). Thus, at first, we have extended the study on inhibitory effect of red ginseng extracts in liver carcinogensis using other experimental mod- els. Furthermore, anti-carcinogenic activity of white gin- seng extracts, besides red ginseng extracts, was also investi- gated. MATERIALS AND METHODS ...

Maxim Pharmaceuticals is a global biopharmaceutical company with a diverse pipeline of drug candidates for life - threatening cancers, hepatitis C and other chronic liver diseases. • Late-stage with four Phase 3 clinical trials • Pipeline targeting multi-billion dollar markets • Program in hepatitis C, a $2 billion market expected to grow to $7 billion by 2011 • Lead drug candidate Ceplene™ efficacy & safety demonstrated in 17 clinical trials in 20 countries • Seasoned, experienced pharmaceutical management • Leading clinical investigators and scientific advisors Ceplene therapy for melanoma represents Maxim’s most advanced program with seven clinical trials in more than 1,000 patients completed or underway. Ceplene clinical data and research has been presented at more than 80 major scientific and clinical meetings ...

When cells in the liver become abnormal, grow out of control and form a cancerous tumor, the disease is called primary liver cancer , also known as malignant hepatoma or hepatocellular carcinoma. (“Hepato” means “ liver .”) Primary liver cancer is not the same disease as cancer that spreads (metastasizes) to the liver from another part of the body (secondary liver cancer ). The liver is often the site of secondary tumors that result from the spread of cancer from another organ, such as the colon or breast. The cancer cells in the secondary tumor are like those of the original cancer , the primary cancer , which is named for the part of the body in which it began. Thus, cancer that begins in the colon or breast and spreads to the liver is called metastatic colon cancer or metastatic breast cancer . What are ...

Background information regarding Austin Health’s new liver cancer treatment What is the treatment for? Certain advanced and inoperable liver cancers. How does it work? The treatment involves using microscopic radiation beads called SIR-Spheres ® that are injected directly into the liver cancers to destroy tumours within the liver that are otherwise inaccessible and inoperable, while minimising harmful side effects to surrounding healthy tissue. For information on the treatment visit www.sirtex.com Can any one with liver cancer have this treatment? Not everyone is suitable for this treatment and must undergo tests in hospital to determine their suitability. How do I find out if I am suitable for this treatment? Visit www.sirtex.com and printout the information to take to your oncologist ( cancer doctor) to discuss your ...